Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · IEX Real-Time Price · USD
2.830
-0.220 (-7.21%)
At close: Jul 19, 2024, 4:00 PM
2.840
+0.010 (0.35%)
Pre-market: Jul 22, 2024, 6:59 AM EDT
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for ALLO stock have an average target of 10.51, with a low estimate of 4.60 and a high estimate of 17. The average target predicts an increase of 271.38% from the current stock price of 2.83.
Analyst Consensus: Buy
* Price targets were last updated on May 31, 2024.
Analyst Ratings
The average analyst rating for ALLO stock from 11 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 4 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 5 | 4 | 4 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 12 | 12 | 12 | 12 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $11 | Buy | Initiates | $11 | +288.69% | May 31, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $13 | Buy | Maintains | $14 → $13 | +359.36% | May 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $9 | Strong Buy | Maintains | $10 → $9 | +218.02% | May 16, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $17 | Strong Buy | Maintains | $17 | +500.71% | May 15, 2024 |
| Stifel | Stifel | Hold Maintains $4.4 → $4.6 | Hold | Maintains | $4.4 → $4.6 | +62.54% | May 14, 2024 |
Financial Forecast
Revenue This Year
50.59K
from 95.00K
Decreased by -46.75%
Revenue Next Year
4.18M
from 50.59K
Increased by 8,170.08%
EPS This Year
-1.52
from -2.09
EPS Next Year
-1.58
from -1.52
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 180,600 | 64.0M | 194.3M | 529.9M | 513.5M |
| Avg | 50,592 | 4.2M | 31.4M | 145.0M | 309.0M |
| Low | n/a | n/a | n/a | n/a | 52.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 90.1% | 126,433.8% | 4,542.9% | 1,589.2% | 254.0% |
| Avg | -46.7% | 8,170.1% | 649.8% | 362.3% | 113.1% |
| Low | - | - | - | - | -64.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.25 | -1.27 | -0.99 | 0.36 | 0.74 |
| Avg | -1.52 | -1.58 | -1.70 | -1.15 | -0.48 |
| Low | -1.87 | -1.98 | -2.21 | -2.07 | -1.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.